2023 World Conference on Lung Cancer (Posters)-EP07.05. Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions

EP07.05. Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions - PDF(Abstract)

Back to course

Pdf Summary

Aumolertinib, a third-generation oral Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI), has shown promising results as a postoperative adjuvant treatment for non-small cell lung cancer (NSCLC) with EGFR mutations. However, its efficacy in treating residual early-stage ground-glass opacity (GGO) lesions in patients who have undergone resection of their main lesion(s) is still unclear. This study aims to investigate the efficacy and safety of aumolertinib as adjuvant therapy in NSCLC patients with EGFR mutations, specifically focusing on its impact on unresected persistent GGO lesions.<br /><br />During the study, 59 patients with pathologically confirmed adenocarcinoma, EGFR mutation-positive, stage IA-IIIA NSCLC were enrolled. All patients were alive with no tumor recurrence as of the cut-off date of April 10, 2023. The study found that aumolertinib had a 1-year disease-free survival rate of 100%, and no grade 3 adverse events occurred during treatment.<br /><br />The study also evaluated the therapeutic effects of aumolertinib on patients with multiple GGO lesions. Among patients with GGO lesions who received postoperative aumolertinib, 66.7% showed a reduction in the size of the lesions, and some lesions completely disappeared.<br /><br />Overall, the study reinforces the effectiveness of aumolertinib as a postoperative adjuvant treatment for NSCLC with an excellent safety profile. It also supports the potential therapeutic efficacy of aumolertinib for patients with persistent GGO lesions. However, larger sample sizes and longer-term follow-up periods are needed to further confirm these findings. Additionally, verifying the presence of EGFR mutations in GGO lesions may enhance the benefits of TKI treatment for such lesions. The study is ongoing to expand the number of patients with GGO lesions and determine longer-term outcomes.

Asset Subtitle

Haitao Ma

Meta Tag

Speaker Haitao Ma

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

Aumolertinib

oral EGFR tyrosine kinase inhibitor

NSCLC

EGFR mutations

postoperative adjuvant treatment

ground-glass opacity lesions

disease-free survival rate

adverse events

therapeutic effects

persistent GGO lesions